Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems
Oncogenic receptor tyrosine kinase (RTK) signaling through the Ras-Raf-Mek-Erk (Ras-MAPK) pathway is implicated in a wide array of carcinomas, including those of the breast. The cyclin-dependent kinases (CDKs) are implicated in regulating proliferative and survival signaling downstream of this pathw...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2013-08-01
|
| Series: | Neoplasia: An International Journal for Oncology Research |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S147655861380098X |
| _version_ | 1818676486011355136 |
|---|---|
| author | Teddy S Nagaria Julia L Williams Charles Leduc Jeremy A Squire Peter A Greer Waheed Sangrar |
| author_facet | Teddy S Nagaria Julia L Williams Charles Leduc Jeremy A Squire Peter A Greer Waheed Sangrar |
| author_sort | Teddy S Nagaria |
| collection | DOAJ |
| description | Oncogenic receptor tyrosine kinase (RTK) signaling through the Ras-Raf-Mek-Erk (Ras-MAPK) pathway is implicated in a wide array of carcinomas, including those of the breast. The cyclin-dependent kinases (CDKs) are implicated in regulating proliferative and survival signaling downstream of this pathway. Here, we show that CDK inhibitors exhibit an order of magnitude greater cytotoxic potency than a suite of inhibitors targeting RTK and Ras-MAPK signaling in cell lines representative of clinically recognized breast cancer (BC) subtypes. Drug combination studies show that the pan-CDK inhibitor, flavopiridol (FPD), synergistically potentiated cytotoxicity induced by the Raf inhibitor, sorafenib (SFN). This synergy was most pronounced at sub-EC50 SFN concentrations in MDA-MB-231 (KRAS-G13D and BRAF-G464V mutations), MDA-MB-468 [epidermal growth factor receptor (EGFR) overexpression], and SKBR3 [ErbB2/EGFR2 (HER-2) overexpression] cells but not in hormone-dependent MCF-7 and T47D cells. Potentiation of SFN cytotoxicity by FPD correlated with enhanced apoptosis, suppression of retinoblastoma (Rb) signaling, and reduced Mcl-1 expression. SFN and FPD were also tested in an MDA-MB-231 mammary fat pad engraftment model of tumorigenesis. Mice treated with both drugs exhibited reduced primary tumor growth rates and metastatic tumor load in the lungs compared to treatment with either drug alone, and this correlated with greater reductions in Rb signaling and Mcl-1 expression in resected tumors. These findings support the development of CDK and Raf co-targeting strategies in EGFR/HER-2-overexpressing or RAS/RAF mutant BCs. |
| first_indexed | 2024-12-17T08:44:14Z |
| format | Article |
| id | doaj.art-8e45cdce4c5a48faadaf023e05e77ac9 |
| institution | Directory Open Access Journal |
| issn | 1476-5586 1522-8002 |
| language | English |
| last_indexed | 2024-12-17T08:44:14Z |
| publishDate | 2013-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neoplasia: An International Journal for Oncology Research |
| spelling | doaj.art-8e45cdce4c5a48faadaf023e05e77ac92022-12-21T21:56:15ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022013-08-0115893995110.1593/neo.13804Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model SystemsTeddy S Nagaria0Julia L Williams1Charles Leduc2Jeremy A Squire3Peter A Greer4Waheed Sangrar5Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, CanadaDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, CanadaDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, CanadaDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, CanadaDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, CanadaDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, CanadaOncogenic receptor tyrosine kinase (RTK) signaling through the Ras-Raf-Mek-Erk (Ras-MAPK) pathway is implicated in a wide array of carcinomas, including those of the breast. The cyclin-dependent kinases (CDKs) are implicated in regulating proliferative and survival signaling downstream of this pathway. Here, we show that CDK inhibitors exhibit an order of magnitude greater cytotoxic potency than a suite of inhibitors targeting RTK and Ras-MAPK signaling in cell lines representative of clinically recognized breast cancer (BC) subtypes. Drug combination studies show that the pan-CDK inhibitor, flavopiridol (FPD), synergistically potentiated cytotoxicity induced by the Raf inhibitor, sorafenib (SFN). This synergy was most pronounced at sub-EC50 SFN concentrations in MDA-MB-231 (KRAS-G13D and BRAF-G464V mutations), MDA-MB-468 [epidermal growth factor receptor (EGFR) overexpression], and SKBR3 [ErbB2/EGFR2 (HER-2) overexpression] cells but not in hormone-dependent MCF-7 and T47D cells. Potentiation of SFN cytotoxicity by FPD correlated with enhanced apoptosis, suppression of retinoblastoma (Rb) signaling, and reduced Mcl-1 expression. SFN and FPD were also tested in an MDA-MB-231 mammary fat pad engraftment model of tumorigenesis. Mice treated with both drugs exhibited reduced primary tumor growth rates and metastatic tumor load in the lungs compared to treatment with either drug alone, and this correlated with greater reductions in Rb signaling and Mcl-1 expression in resected tumors. These findings support the development of CDK and Raf co-targeting strategies in EGFR/HER-2-overexpressing or RAS/RAF mutant BCs.http://www.sciencedirect.com/science/article/pii/S147655861380098X |
| spellingShingle | Teddy S Nagaria Julia L Williams Charles Leduc Jeremy A Squire Peter A Greer Waheed Sangrar Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems Neoplasia: An International Journal for Oncology Research |
| title | Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems |
| title_full | Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems |
| title_fullStr | Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems |
| title_full_unstemmed | Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems |
| title_short | Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems |
| title_sort | flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in egfr her 2 and mutant ras raf breast cancer model systems |
| url | http://www.sciencedirect.com/science/article/pii/S147655861380098X |
| work_keys_str_mv | AT teddysnagaria flavopiridolsynergizeswithsorafenibtoinducecytotoxicityandpotentiateantitumorigenicactivityinegfrher2andmutantrasrafbreastcancermodelsystems AT julialwilliams flavopiridolsynergizeswithsorafenibtoinducecytotoxicityandpotentiateantitumorigenicactivityinegfrher2andmutantrasrafbreastcancermodelsystems AT charlesleduc flavopiridolsynergizeswithsorafenibtoinducecytotoxicityandpotentiateantitumorigenicactivityinegfrher2andmutantrasrafbreastcancermodelsystems AT jeremyasquire flavopiridolsynergizeswithsorafenibtoinducecytotoxicityandpotentiateantitumorigenicactivityinegfrher2andmutantrasrafbreastcancermodelsystems AT peteragreer flavopiridolsynergizeswithsorafenibtoinducecytotoxicityandpotentiateantitumorigenicactivityinegfrher2andmutantrasrafbreastcancermodelsystems AT waheedsangrar flavopiridolsynergizeswithsorafenibtoinducecytotoxicityandpotentiateantitumorigenicactivityinegfrher2andmutantrasrafbreastcancermodelsystems |